Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World CongressGlobeNewsWire • 05/07/25
Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On DeckSeeking Alpha • 04/15/25
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual MeetingGlobeNewsWire • 04/08/25
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual MeetingGlobeNewsWire • 04/03/25
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated MilestonesGlobeNewsWire • 03/03/25
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewsWire • 02/26/25
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual MeetingGlobeNewsWire • 02/13/25
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/07/25
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)GlobeNewsWire • 12/16/24
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated MilestonesGlobeNewsWire • 11/14/24
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 MeetingGlobeNewsWire • 10/22/24
Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBSSeeking Alpha • 08/17/24
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific MeetingGlobeNewsWire • 07/11/24
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual MeetingGlobeNewsWire • 06/25/24
Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a BetZacks Investment Research • 06/05/24
Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In PlaceSeeking Alpha • 06/04/24